Hsa-miR-483-5p/mRNA network that regulates chemotherapy resistance in locally advanced rectal cancer identified through plasma exosome transcriptomics

Table 1 The College of American Pathologists standards and the group information

The criteria of CAP standards for the assessment of tumor response to nCRT
Good responder	CAP0	Complete response with no viable tumor cells
	CAP1	Only small clusters or single cancer cells remained
Poor-responder	CAP2	Residual tumor cells remaining, but with predominant fibrosis
	CAP3	Poor response with extensive residual tumor cells
The sub-group information of this study
Groups	Group 1	Poor responders before nCRT
	Group 2	Good responders before nCRT
	Group 3	Poor responders after nCRT
	Group 4	Good responders after nCRT

nCRT: Neoadjuvant chemoradiotherapy; CAP: College of American Pathologists.

Table 2 The differential profiles of exosome microRNAs in poor- and good responders

Pre-nCRT (G1 vs G2)				Post-nCRT (G3 vs G4)
miRNAs	Log2FC	P value	Regulation	miRNAs	Log2FC	P value	Regulation
MiR-493-5p	4.64	0.001	Up	MiR-516a-5p	4.74	0.041	Up
MiR-332a-3p	3.85	0.018	Up	MiR-378 g	2.98	0.047	Up
MiR-4324	2.89	0.043	Up	MiR-150-3p	2.38	0.036	Up
MiR-335-3p	2.33	0.001	Up	MiR-483-5p	1.65	0.001	Up
MiR-1303	2.25	0.048	Up	MiR-582-3p	1.16	0.032	Up
MiR-2355-3p	-4.61	0.006	Down	MiR-4497	-4.44	0.026	Down
MiR-184	-4.37	0.027	Down	MiR-935	-3.09	0.029	Down
MiR-5187-5p	-4.33	0.015	Down	MiR-4516	-2.18	0.044	Down
MiR-122-3p	-4.37	0.027	Down	MiR-486-3p	-2.09	0.041	Down
MiR-378a-5p	-3.49	0.001	Down	MiR-651-5p	-1.73	0.032	Down

nCRT: Neoadjuvant chemoradiotherapy; miRNAs: MicroRNAs.